Literature DB >> 17940235

Adult cystic fibrosis.

Michael P Boyle1.   

Abstract

Cystic fibrosis is a multisystem disease characterized primarily by chronic pulmonary infection and bronchiectasis, pancreatic exocrine impairment, and elevated sweat chloride. In the last 4 decades, new treatment strategies and aggressive nutritional management have resulted in a significant increase in expected survival, with median predicted survival in cystic fibrosis now to older than 35 years. This increase in predicted survival has also been aided by a greater appreciation of the potential variability in the presentation and severity of cystic fibrosis, resulting in identification of a growing number of mild cases. As it is estimated that within the next decade more than half of all individuals with cystic fibrosis will be aged 18 years or older, adult medicine caregivers are increasingly likely to encounter patients with cystic fibrosis and be exposed to their unique medical management.

Entities:  

Mesh:

Year:  2007        PMID: 17940235     DOI: 10.1001/jama.298.15.1787

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  26 in total

1.  ATS Core Curriculum 2015. Part I: Adult Pulmonary Medicine.

Authors:  Gaëtane C Michaud; Colleen L Channick; Chad R Marion; Robert M Tighe; James A Town; Andrew M Luks; Jeremy B Richards; Sucharita Kher; Prerna Mota; Gina Hong; Natalie E West; Craig Rackley; Luke Neilans; Josanna Rodriguez-Lopez; Hilary DuBrock; Cassie C Kennedy; Diana J Kelm; Carey C Thomson
Journal:  Ann Am Thorac Soc       Date:  2015-09

Review 2.  Update in cystic fibrosis 2007.

Authors:  Frank J Accurso
Journal:  Am J Respir Crit Care Med       Date:  2008-05-15       Impact factor: 21.405

3.  An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis.

Authors:  Christopher M Oermann; George Z Retsch-Bogart; Alexandra L Quittner; Ronald L Gibson; Karen S McCoy; A Bruce Montgomery; Peter J Cooper
Journal:  Pediatr Pulmonol       Date:  2010-11

Review 4.  Silencing human genetic diseases with oligonucleotide-based therapies.

Authors:  Tamara Martínez; Natalia Wright; Marta López-Fraga; Ana Isabel Jiménez; Covadonga Pañeda
Journal:  Hum Genet       Date:  2013-03-14       Impact factor: 4.132

5.  Section 3: Prevention and Treatment of AKI.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-03

6.  Chronic osteitic rhinosinusitis as a manifestation of cystic fibrosis: A case report.

Authors:  Aniket B Jadhav; Alan G Lurie; Aditya Tadinada
Journal:  Imaging Sci Dent       Date:  2014-09-17

Review 7.  What's new in cystic fibrosis? From treating symptoms to correction of the basic defect.

Authors:  Marijke Proesmans; François Vermeulen; Kris De Boeck
Journal:  Eur J Pediatr       Date:  2008-04-04       Impact factor: 3.183

8.  AMPK agonists ameliorate sodium and fluid transport and inflammation in cystic fibrosis airway epithelial cells.

Authors:  Michael M Myerburg; J Darwin King; Nicholas M Oyster; Adam C Fitch; Amy Magill; Catherine J Baty; Simon C Watkins; Jay K Kolls; Joseph M Pilewski; Kenneth R Hallows
Journal:  Am J Respir Cell Mol Biol       Date:  2009-07-17       Impact factor: 6.914

9.  Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis.

Authors:  Misagh Alipour; Zacharias E Suntres; Majed Halwani; Ali O Azghani; Abdelwahab Omri
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240

10.  Preliminary evidence for cell membrane amelioration in children with cystic fibrosis by 5-MTHF and vitamin B12 supplementation: a single arm trial.

Authors:  Cinzia Scambi; Lucia De Franceschi; Patrizia Guarini; Fabio Poli; Angela Siciliano; Patrizia Pattini; Andrea Biondani; Valentina La Verde; Oscar Bortolami; Francesco Turrini; Franco Carta; Ciro D'Orazio; Baroukh M Assael; Giovanni Faccini; Lisa M Bambara
Journal:  PLoS One       Date:  2009-03-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.